June 20, 2025 11:38 AM EDTUpdated 01:28 PM

Pharma companies are weighing how a drug’s IP location could impact tariffs

Anna Brown

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Early-stage investor Syncona readjusts priorities due to bleak biotech market

Inside the FDA’s ‘listening’ tour: Officials agree US lags behind China on drug development

Roche's venture arm chief to step down in 2026; AstraZeneca obesity leader has retired

UK's NICE says Lilly, Eisai's Alzheimer's drugs aren't worth national coverage

sponsored

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?